On Friday, Shares of Hilton Worldwide Holdings Inc. (NYSE:HLT), gained 0.32% to $28.08.
Hilton Worldwide Holdings, will report second quarter financial results preceding to the stock market open on Wednesday, July 29, 2015, followed by a conference call at 10:00 a.m. Eastern Time. Christopher J. Nassetta, Hilton Worldwide’s president and chief executive officer, and Kevin Jacobs, Hilton Worldwide’s executive vice president and chief financial officer, will talk about the company’s performance and lead a question-and-answer session.
Hilton Worldwide Holdings Inc., a hospitality company, owns, leases, manages, develops, and franchises hotels, resorts, and timeshare properties worldwide. The company operates hotels under 12 brand names, counting Hilton Hotels & Resorts, Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Curio - A Collection by Hilton, DoubleTree by Hilton, Embassy Suites Hotels, Hilton Garden Inn, Hampton Hotels, Homewood Suites by Hilton, Home2 Suites by Hilton, and Hilton Grand Vacations.
Shares of Baxter International Inc. (NYSE:BAX), declined -0.58% to $71.92, during its last trading session.
Merrimack Pharmaceuticals, Inc. (MACK) and Baxalta Incorporated, a wholly-owned partner of Baxter International Inc (BAX), jointly declared that the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as “nal-IRI,” has been accepted for review by the U.S. Food and Drug Administration (FDA). Merrimack is seeking U.S. marketing approval of MM-398 for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been formerly treated with gemcitabine-based therapy.
In addition, the FDA has classified the NDA as having Priority Review status. A Priority Review designation is for drugs that treat serious conditions and, if approved, would provide noteworthy improvements in the safety or effectiveness of the treatment of serious conditions contrast to accessible therapies. The FDA has set a aim of October 24, 2015 to take action under the Prescription Drug User Fee Act (PDUFA).
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Finally, Seres Therapeutics, Inc. (NASDAQ:MCRB), ended its last trade with 185.56% surge, and closed at $51.40.
Seres Therapeutics, declared the pricing of its initial public offering of 7,430,555 shares of common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Seres Therapeutics. In addition, Seres Therapeutics granted the underwriters a 30-day option to purchase up to an additional 1,114,583 shares of common stock from the company at the public offering price.
Goldman, Sachs & Co. and BofA Merrill Lynch are acting as joint book-running managers for the offering, and Leerink Partners and Canaccord Genuity Inc. are acting as lead managers for the offering.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has accomplished open label Phase Ib/2 clinical study for the prevention of further recurrences of Clostridium difficile infection (CDI).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
